Novartis’ Cosentyx delivers mixed results in EXCEED trial in active PsA

This article was originally published here

Cosentyx, which is an inhibitor of interleukin-17A (IL-17A), could not show statistical significance for superiority in ACR 20 over the AbbVie drug in the head-to-head late-stage trial. As

The post Novartis’ Cosentyx delivers mixed results in EXCEED trial in active PsA appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply